Oncoinvent AS: Oncoinvent Presents Preliminary 18-Month Safety and Efficacy Data from Ongoing RAD-18-002 Phase 1/2A Trial of Radspherin in Colorectal Cancer Patients at the 13th PSOGI International Congress on Peritoneal Surface Malignancies finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
The company makes three important new appointments to the clinical and regulatory teams in preparation for the upcoming Radspherin® phase 2 clinical trialsOSLO, Norway (BUSINESS WIRE) Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, tod.